References
- Gordon T, Kannel W B. The Framingham study. Government Printing office, Washington 1974, Section 30 (DHEW publ. no. NIH74—599)
- Shaper A G. Risk factors for ischaemic heart disease. Health Trends 1987; 19: 3–8
- Martin M J, Hulley S B, Browner W S, Kuller L H, Wentworth D. Serum cholesterol, blood pressure and mortality. Implications from a cohort of 361662 men. Lancet, ii: 933–936
- Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465–1477
- MacMahon S W, MacDonald G J. Antihypertensive treatment and plasma lipoprotein levels. The associations in data from a population study. Am J Med 1986; 80(suppl 2A)40–47
- Williams R R, Hunt S C, Hopkins P N, et al. Familial dyslipidemic hypertension. JAMA 1988; 24: 3579–3586
- Stamler J, Wentworth D, Neaton J D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded?. JAMA 1986; 20: 2823–2828
- Costa M E, D'Agostino R B, Belanger A J, Kannel W B, Chobanian A V. Mild hypertension and hypercholesterolemia in young people: The Framingham Offspring study. Circulation 1988; 78(suppl 2)11–567, abstr
- Assmann G, Schulte H. The prospective Cardiovascular Munster Study. Prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol 1987; 59: 9G–17G
- Pollare T. Disturbances in carbohydrate and lipid metabolism in patients with primary hypertension. Acta Universitatis Upsaliensis, Uppsala 1989, Thesis
- Tamira M, Kuwano H, Kinoshita T, et al. Identification of lino-leic and oleic acids as endogenous Na+,K+-ATPase inhibitors from acute volume-expanded hog plasma. J Biol Chem 1985; 260: 9672–9277